Organon & Co | OGN - Assets


Organon & Co reported $13.55B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Celltrion KRW 21.08T 530.63B Sep/2025
Cspc Pharmaceutical CNY 46B 1.61B Jun/2025
Deva Holding AS TRY 12.93B 1.83B Sep/2023
Dianthus Therapeutics USD 577.44M 251.37M Sep/2025
Divis Laboratories Ltd INR 181.51B 12.19B Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Kangmei Pharma CNY 13.68B 38.19M Sep/2025
Knight Therapeutics CAD 962.29M 16.93M Sep/2024
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 66.4M 1.06M Jun/2025
Merck USD 129.55B 12.02B Sep/2025
Neuren Pharmaceuticals AUD 331.25M 78.46M Jun/2025
Novartis USD 107.29B 2.89B Sep/2025
Organigram Holdings CAD 562.21M 2.4M Sep/2025
Organon & Co USD 13.55B 52M Sep/2025
Ovoca Bio EUR 11.41M 3.36M Jun/2022
Pharma Mar EUR 341.66M 6.59M Sep/2025
Qiagen NV USD 6.3B 257.54M Dec/2025
Sartorius EUR 9.61B 413.4M Sep/2025
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Tilray USD 2.07B 1.33B Mar/2025